{"classes":[{"categories":[{"measurements":[{"comment":"NA = not estimable as there were not enough events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Time to disease progression is the time from the date of first study drug intake to the date of event defined as the first progression to AP or BC (from CP) or to BC (from AP) or the date of CML-related death occurring on treatment, whichever was earlier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients resistant or intolerant to either imatinib or dasatinib","id":"OG000","title":"Resistant/Intolerant Ph+ CML in CP"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS): All patients who received at least one dose of study medication","reportingStatus":"POSTED","timeFrame":"From first dosing to the disease progression within 66 cycles","title":"Time to Disease Progression for Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients - Kaplan-Meier Estimates","type":"SECONDARY","unitOfMeasure":"months"}